A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection.
Wafaa B AlsoussiJackson S TurnerJames Brett CaseHaiyan ZhaoAaron J SchmitzJulian Q ZhouRita E ChenTingting LeiAmena A RizkKatherine M McIntireEmma S WinklerJulie M FoxNatasha M KafaiLarissa B ThackrayAhmed O HassanFatima AmanatFlorian KrammerCorey T WatsonSteven H KleinsteinDaved H FremontMichael S DiamondAli H EllebedyPublished in: Journal of immunology (Baltimore, Md. : 1950) (2020)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for millions of infections and hundreds of thousands of deaths globally. There are no widely available licensed therapeutics against SARS-CoV-2, highlighting an urgent need for effective interventions. The virus enters host cells through binding of a receptor-binding domain within its trimeric spike glycoprotein to human angiotensin-converting enzyme 2. In this article, we describe the generation and characterization of a panel of murine mAbs directed against the receptor-binding domain. One mAb, 2B04, neutralized wild-type SARS-CoV-2 in vitro with remarkable potency (half-maximal inhibitory concentration of <2 ng/ml). In a murine model of SARS-CoV-2 infection, 2B04 protected challenged animals from weight loss, reduced lung viral load, and blocked systemic dissemination. Thus, 2B04 is a promising candidate for an effective antiviral that can be used to prevent SARS-CoV-2 infection.
Keyphrases
- respiratory syndrome coronavirus
- sars cov
- wild type
- angiotensin converting enzyme
- weight loss
- binding protein
- coronavirus disease
- angiotensin ii
- induced apoptosis
- endothelial cells
- dna binding
- bariatric surgery
- small molecule
- heart rate
- blood pressure
- physical activity
- resistance training
- roux en y gastric bypass
- body mass index
- adipose tissue
- metabolic syndrome
- skeletal muscle